Navigation Links
Cortex Area Thinner in Youth with Alzheimers-Related Gene

cations/UnravelingTheMystery/Part1/Hallmarks.htm">http://www.nia.nih.gov/Alzheimers/Publications/UnravelingTheMystery/Part1/Hallmarks.htm) characteristic of the disorder.

Previous studies had also implicated in Alzheimers one of three versions of a gene that produces ApoE. The ApoE4 variant occurs in 10-25 percent of the general population, but in 40 percent of late-onset Alzheimers patients. The strongest genetic risk factor for the disease discovered to date, ApoE4 has been linked to altered brain activity in adults and impaired neuronal development.

Shaw and colleagues suspected that youth with ApoE4 would have a thinner entorhinal cortex. To confirm this, they compared the MRI (magnetic resonance imaging) scans of 239 healthy children and teens with their ApoE gene types. Many were re-scanned as they grew up to see if there was any ongoing thinning process traceable to ApoE4.

Each individual inherits two copies of the ApoE gene, one from each parent. Youth with at least one copy of the relatively rare ApoE2 variant — which may confer a protective effect against developing Alzheimers — showed the thickest entorhinal cortex. This was the first evidence that the ApoE2 version, which is carried by 5-10 percent of the population, affects brain structure, say the researchers. Youth with two copies of ApoE3, the most common version (65-85 percent prevalence), had intermediate cortex thickness. Those with one or two copies of ApoE4 had the thinnest entorhinal cortex.

ApoE4 gene type also predicted thinning of two other brain regions (medial temporal and posterior orbitofrontal areas) affected early in Alzheimers disease, which, like the entorhinal cortex, are involved in learning and memory. The pattern of changes resembled that seen in early Alzheimers, but to a far lesser degree. For example, the entorhinal cortex thinning seen in Alzheimers disease is about 10-fold greater than in the youth with ApoE4.

Although they
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cortex Area Thinner Youth with Alzheimers Related Gene
(Date:12/1/2008)... ROCKVILLE, Md., Dec. 1 ...rts publication in The Lancet , one of the world,...ials of its novel circadian regulator, experimenta... by Rajaratnam et al(1) is entitled "Melatonin ago...after sleep-time shift: two randomised controlled ...
(Date:12/1/2008)... St. Jude study shows the Prox1 gene is a two-way...thelial cells to be reprogrammed so that they lose...lial cells , , MEMPHIS, Tenn., Dec. 1 /PRNe...dren,s Research Hospital have discovered that a ce...ge its identity that it requires the constant expr...
(Date:12/1/2008)... ATLANTA, Dec. 1 GeoVax...a-based biotechnology company developing,human va...eficiency Virus) and,other infectious agents, ann...,Vaccine Trials will take place in twelve sites a...onducted in collaboration with The National Instit...
(Date:11/28/2008)... INDIANAPOLIS, Nov. 28 ...n its supplemental New Drug Application (sNDA) fro... Cymbalta(R) (duloxetine HCl),for the management ...cation in,the first half of 2009, adding data fro...osteoarthritis pain of the knee. , The deci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 1UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 2UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 3UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 1NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 2NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 3NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 5Shape Shifting on Veterans Day 5756 1Shape Shifting on Veterans Day 5756 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 1More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 3More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 4
...LE, Calif., April 16, 2007 /PRNewswire-FirstCall/ ...anism of action of,its anti-cancer agent BZL101, w...r late stage breast cancer at the American,Associa...os Angeles,Convention Center in Los Angeles, CA, A...n will describe the pathway for,cancer cell apopto...
...agonist Demonstrates Clinical Activity, a Novel Me...other HCV Inhibitors-, NEW HAVEN, Conn., April 16,...uticals, Inc. today announced the presentation of,... one of,Achillion,s NS4A antagonists, ACH-806, for...n at the 42nd Annual Meeting of the,European Assoc...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
(Date:12/2/2008)...rathon Health, a leading provider of onsite health...that New Balance, the athletic products company, h...and manage onsite health clinics and to provide he... in Maine , Burlington, V...eading provider of onsite employee health services...
(Date:12/2/2008)...r many families, the problem with the holidays is ...sight into how caregivers of aging parents can bri... experience. , San Mateo,...the stress of the holiday season is family, especi...expert Esther Koch , founder of Encore Managemen...
(Date:12/2/2008)...tional Non-profit Launches Age-related Macular Deg...Cost to Eligible Patients and Free Eye-Healthy Coo...A (Vocus) December 2, 2008 -- "Do You See Wha...disease known as Age-related Macular Degeneration ..., ,Picture this…. a large black hole in the...
(Date:12/2/2008)...ion Health announces that the SouthEast Alaska Reg..., has selected the Rhapsody™ Integration Eng..., radiology, pharmacy, laboratory and business pro...o extend connectivity to statewide systems such as...y) and AKAIMS (an MIS and clinical documentation t...
Breaking Medicine News(10 mins):Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3
...ne of the top organ transplant hospitals in Califo...egations a Saudi national improperly received an o...nts.// The Los Angeles Times reported that offici... discovered that, following the transplant, some h...
...w new hope on the horizon for trigeminal neuralgia...fe Stereotactic Radiosurgery (GKRS) is an effectiv...n.// Researchers at the Comprehensive Cancer Cent...Medical found that the GKRS technique relived pain...
...nal survey conducted by Synovate India and sponsor... though Indians use high quality toothbrush and th... level of oral hygiene awareness was surprisingly ... admitted that they have never been to a dentist i...
...In what is the first promising news regarding the ...rvices department (ANTSZ) has said that a prototyp... proving effective against birds. 'The effectiven...he Asian H5N1 strain of bird flu is proved among p...
Other Medicine News:
A fully automated, random access immunoassay instrument with over 50 assays available worldwide. thyroid, reproductive endocrinology, tumor marker, therapeutic drug, serology, anemia and cardiac test
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t
The Embla 96/384 well washer is a top-loading, robotic-compatible plate washer for 96- and 384-well microplate washing. It is ideal for ELISAs and most cell applications.
Elisa Plate Reader
Medicine Products: